Paper25907296
S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways.
Wu R and 6 others. Exp Cell Res, 2015. Cited by 74 papers, by iCite.
Cite this record
ConductScience Library. S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways. Papers, record 25907296. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25907296
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- S100A9 promotes human hepatocellular carcinoma cell growth and invasion through RAGE-mediated ERK1/2 and p38 MAPK pathways.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Calgranulin B | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| MAP Kinase Signaling System | Major topic |
| Neoplasm Invasiveness | Major topic |
| Receptors, Immunologic | Major topic |
| p38 Mitogen-Activated Protein Kinases | Major topic |
| Animals | |
| Cell Proliferation | |
| Cells, Cultured | |
| Disease Models, Animal | |
| Female | |
| Hep G2 Cells | |
| Humans | |
| Liver Neoplasms, Experimental | |
| Mice | |
| Mice, Nude | |
| Mitogen-Activated Protein Kinase 1 | |
| Mitogen-Activated Protein Kinase 3 | |
| Receptor for Advanced Glycation End Products |
Source PubMed
Cited by56
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 74 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42675222 | Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer. | Oncogene | 2026 | https://conductscience.org/library/papers/42675222 | PubMed |
| 41513624 | Site-specific HPV18 integration facilitates cervical carcinogenesis through metabolic reprogramming-induced dysfunction of the SpHK1/S1P/S1PR1 pathway. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/41513624 | PubMed |
| 41272764 | S100A9 regulates eosinophil extracellular trap and activates NF-κB signaling in endometrial cancer: a machine learning-based biomarker discovery. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41272764 | PubMed |
| 41009692 | Emerging Biomarkers in Urological Cancers: Angiogenesis and Damage-Associated Molecular Pattern Signaling. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41009692 | PubMed |
| 40909863 | The Role of MAPK12 in Prognosis of Patients With Liver Cancer and Effects on Stemness Characteristics. | Stem Cells Int | 2025 | https://conductscience.org/library/papers/40909863 | PubMed |
| 40544243 | Edaravone-Dexborneol slows down pathological progression and cognitive decline via inhibiting S100A9 in APPswe/PS1dE9 mice. | Alzheimers Res Ther | 2025 | https://conductscience.org/library/papers/40544243 | PubMed |
| 39844891 | Expression of miR-15b-5p and toll-like receptor4 as potential novel diagnostic biomarkers for hepatitis C virus-induced hepatocellular carcinoma. | Noncoding RNA Res | 2025 | https://conductscience.org/library/papers/39844891 | PubMed |
| 39638834 | Machine learning approach identifies inflammatory gene signature for predicting survival outcomes in hepatocellular carcinoma. | Sci Rep | 2024 | https://conductscience.org/library/papers/39638834 | PubMed |
| 39262476 | Identifying epithelial-mesenchymal transition-related genes as prognostic biomarkers and therapeutic targets of hepatocellular carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data. | Transl Cancer Res | 2024 | https://conductscience.org/library/papers/39262476 | PubMed |
| 38817853 | S100A8-Mediated Inflammatory Signaling Drives Colorectal Cancer Progression via the CXCL5/CXCR2 Axis. | J Cancer | 2024 | https://conductscience.org/library/papers/38817853 | PubMed |
| 37994394 | Integration of single-cell and bulk RNA-sequencing to analyze the heterogeneity of hepatocellular carcinoma and establish a prognostic model. | Cancer Rep (Hoboken) | 2024 | https://conductscience.org/library/papers/37994394 | PubMed |
| 37990105 | EMT-related gene risk model establishment for prognosis and drug treatment efficiency prediction in hepatocellular carcinoma. | Sci Rep | 2023 | https://conductscience.org/library/papers/37990105 | PubMed |
| 37405532 | Establishment and Evaluation of Exosomes-Related Gene Risk Model in Hepatocellular Carcinoma. | Biochem Genet | 2024 | https://conductscience.org/library/papers/37405532 | PubMed |
| 36982351 | Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36982351 | PubMed |
| 36421698 | Culture of Cancer Cells at Physiological Oxygen Levels Affects Gene Expression in a Cell-Type Specific Manner. | Biomolecules | 2022 | https://conductscience.org/library/papers/36421698 | PubMed |
| 36232334 | S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36232334 | PubMed |
| 36041055 | S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression. | Adv Sci (Weinh) | 2022 | https://conductscience.org/library/papers/36041055 | PubMed |
| 35992798 | Construction and experimental verification of user-friendly molecular subtypes mediated by immune-associated genes in hepatocellular carcinoma. | Front Oncol | 2022 | https://conductscience.org/library/papers/35992798 | PubMed |
| 35397536 | A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. | BMC Cancer | 2022 | https://conductscience.org/library/papers/35397536 | PubMed |
| 35281615 | Differential Expression and Bioinformatics Analysis of tRF/tiRNA in Endometriosis Patients. | Biomed Res Int | 2022 | https://conductscience.org/library/papers/35281615 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AGER | 177 | PubTator's text mining | https://conductscience.org/library/genes/177 | NCBI Gene |
| MAPK1 | 5594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
| MAPK3 | 5595 | PubTator's text mining | https://conductscience.org/library/genes/5595 | NCBI Gene |
| S100A9 | 6280 | PubTator's text mining | https://conductscience.org/library/genes/6280 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/25907296
GET https://conductscience.org/api/papers/v1/25907296/cited_by?page=2